Literature DB >> 3265957

Anticentromere antibodies--clinical correlates.

J P Wade1, B Sack, P H Schur.   

Abstract

We tested 11,594 consecutive sera for antinuclear antibodies and 1,502 were found to be positive; 68 patients (72 sera) had anticentromere antibodies. A retrospective analysis of the clinical characteristics and diagnoses of patients found to have anticentromere antibodies were correlated and showed a diverse array of findings. The association of anticentromere antibodies and the CREST variant of scleroderma may be less specific than originally thought when used as a screening test in an unselected population with rheumatic disease. Anticentromere antibody was present in patients with drug induced lupus, a finding not previously reported.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265957

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Utility of serologic testing in the diagnosis of noninfectious pulmonary disorders.

Authors:  R H White; J A Golden
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

3.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

4.  Anticentromere antibodies in subjects with no apparent connective tissue disease.

Authors:  S L Lee; G J Tsay; R T Tsai
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

5.  Clinical correlation of anticentromere antibodies.

Authors:  M Zuber; R Gotzen; I Filler
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.